Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimal Residual Disease-directed Therapy for Low-risk and Intermediate-risk Acute Myeloid Leukemia.

NCT02870777 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT02870777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02870777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimal Residual Disease-directed Therapy for Low-risk and Intermediate-risk Acute Myeloid Leukemia.
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2016
Completion date
December 31, 2019
Enrollment
743 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, minimal residual disease